On June 9, Shougang LanzaTech (02553.HK) rose 9.25% in regular trading, trading at HK$32.84/share, with trading volume of HK$52.28 million.

On the news front, the company announced on June 8 that its CO2-containing industrial tail gas biological synthesis anhydrous ethanol project (Hebei Shoulang Phase II) successfully completed seed tank dry powder inoculation, officially entering the trial production stage. This marks the world's first industrial-scale application demonstration of this technology pathway.

The project adopts the company's proprietary second-generation negative carbon technology, which directly consumes 0.5 tons of CO2 per ton of ethanol produced, achieving a carbon fixation rate of 93.5%. The technology has been certified as reaching international leading standards by the China Petroleum and Chemical Industry Federation. Since its IPO on June 3 at HK$14.6/share, the stock has surged over 130%, with public offering oversubscribed approximately 1,421 times. The company holds a 58.4% global market share by revenue in the commercialized synthetic biology CCUS sector and plans to construct a sustainable aviation fuel facility in Baotou, Inner Mongolia for production in 2027.

Shougang LanzaTech, established in 2011, is the first company in the CCUS industry to achieve commercialization and scale-up of low-carbon products using verified synthetic biology technology, operating four production facilities across China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)